TY - JOUR
T1 - Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation
AU - Tveit, Arnljot
AU - Seljeflot, Ingebjørg
AU - Grundvold, Irene
AU - Abdelnoor, Michael
AU - Smith, Pal
AU - Arnesen, Harald
N1 - Funding Information:
This study was sponsored by the Regional Health Corporation of Eastern Norway, Hamar, and the Medical Research Foundation, Asker & Baerum Hospital, Rud, Norway. AstraZeneca, Molndal, Sweden, provided the study medication, and AstraZeneca, Oslo, Norway, supported the study with a grant to cover laboratory analyses.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF). One hundred seventy-one patients with persistent AF were randomly assigned to receive candesartan 8 mg/day or placebo for 3 to 6 weeks before and candesartan 16 mg/day or placebo for 6 months after electrical cardioversion. Serum levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α, interleukin-6, P-selectin, E-selectin, CD-40 ligand, and vascular cell adhesion molecule-1 were measured at baseline and end of study. Compared with patients with a relapse of AF, patients still in sinus rhythm at 6 months after cardioversion (n = 40) had lower baseline hs-CRP and E-selectin levels: median 2.36 mg/L (25th, 75th percentiles 1.28, 4.09) versus 3.44 mg/L (25th, 75th percentiles 1.66, 6.05, p = 0.031) and 32 ng/ml (25th, 75th percentiles 23, 42) versus 37 ng/ml (25th, 75th percentiles 28, 51, p = 0.042), respectively. Neither sustained sinus rhythm for 6 months nor treatment with candesartan had an impact on measured concentrations of markers of inflammation. In conclusion, low hs-CRP and E-selectin at baseline were associated with maintenance of sinus rhythm after electrical cardioversion.
AB - Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF). One hundred seventy-one patients with persistent AF were randomly assigned to receive candesartan 8 mg/day or placebo for 3 to 6 weeks before and candesartan 16 mg/day or placebo for 6 months after electrical cardioversion. Serum levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α, interleukin-6, P-selectin, E-selectin, CD-40 ligand, and vascular cell adhesion molecule-1 were measured at baseline and end of study. Compared with patients with a relapse of AF, patients still in sinus rhythm at 6 months after cardioversion (n = 40) had lower baseline hs-CRP and E-selectin levels: median 2.36 mg/L (25th, 75th percentiles 1.28, 4.09) versus 3.44 mg/L (25th, 75th percentiles 1.66, 6.05, p = 0.031) and 32 ng/ml (25th, 75th percentiles 23, 42) versus 37 ng/ml (25th, 75th percentiles 28, 51, p = 0.042), respectively. Neither sustained sinus rhythm for 6 months nor treatment with candesartan had an impact on measured concentrations of markers of inflammation. In conclusion, low hs-CRP and E-selectin at baseline were associated with maintenance of sinus rhythm after electrical cardioversion.
UR - http://www.scopus.com/inward/record.url?scp=34248632821&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2007.01.030
DO - 10.1016/j.amjcard.2007.01.030
M3 - Article
C2 - 17531578
AN - SCOPUS:34248632821
SN - 0002-9149
VL - 99
SP - 1544
EP - 1548
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 11
ER -